Half-year report · HY
8129.TEDINET S100X3KF
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥767.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥1.52T | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥755.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥7.3bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥7.4bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥8.3bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥20.7bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.6bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥9.1bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥8.5bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥6.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥19.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥6.3bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥5.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥754.9bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥722.8bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥770.7bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥487.9bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥465.9bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥267.0bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥256.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥262.6bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥96.5bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥86.5bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥89.5bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥78.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥103.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥128.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥25.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥26.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥10.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥3.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥12.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥20.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥10.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥99.12 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥313.2 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.71 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥92.72 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥284.22 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥75.64 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 35.3% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.5% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.1% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥30.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥30.1bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥1.3bn |
| Dispensing Pharmacyreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥49.5bn |
| Dispensing Pharmacyreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥49.5bn |
| Dispensing Pharmacyreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥2m |
| Dispensing Pharmacyreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥600m |
| Medical Products Manufacturing And Salesreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.7bn |
| Medical Products Manufacturing And Salesreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥4.4bn |
| Medical Products Manufacturing And Salesreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥120m |
| Medical Products Retailreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥739.2bn |
| Medical Products Retailreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥714.2bn |
| Medical Products Retailreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥24.9bn |
| Medical Products Retailreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥7.3bn |
| Other Related Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.6bn |
| Other Related Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.8bn |
| Other Related Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥746m |
| Other Related Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥475m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥798.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥767.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥30.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥8.5bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥29.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥29.7bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.3bn |
| Dispensing Pharmacyreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥47.1bn |
| Dispensing Pharmacyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥47.1bn |
| Dispensing Pharmacyreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥19m |
| Dispensing Pharmacyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥18m |
| Medical Products Manufacturing And Salesreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| Medical Products Manufacturing And Salesreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.4bn |
| Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| Medical Products Manufacturing And Salesreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥442m |
| Medical Products Retailreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥728.7bn |
| Medical Products Retailreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥704.3bn |
| Medical Products Retailreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥24.4bn |
| Medical Products Retailreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥8.0bn |
| Other Related Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.2bn |
| Other Related Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.2bn |
| Other Related Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥994m |
| Other Related Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥203m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥784.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥755.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥29.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥8.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 586
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents | Prior2YearInstant | 128673000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 78226000000 | JPY |
| Increase in cash and cash equivalents resulting from merger with unconsolidated subsidiaries cce | Prior1InterimDuration | 774000000 | JPY |
| Increase in cash and cash equivalents resulting from merger with unconsolidated subsidiaries cce | InterimDuration | 515000000 | JPY |
| Increase decrease in cash and cash equivalents resulting from change of scope of consolidation cce | Prior1InterimDuration | － | JPY |
| Increase decrease in cash and cash equivalents resulting from change of scope of consolidation cce | InterimDuration | 767000000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 103925000000 | JPY |
| Cash and cash equivalents | InterimInstant | 89543000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02608-000MedicalProductsRetailReportableSegmentsMember | 704284000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02608-000DispensingPharmacyReportableSegmentsMember | 47092000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 1382000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02608-000OtherRelatedBusinessReportableSegmentMember | 2214000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 754974000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 754974000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02608-000MedicalProductsRetailReportableSegmentsMember | 24448000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02608-000DispensingPharmacyReportableSegmentsMember | 19000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 4209000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02608-000OtherRelatedBusinessReportableSegmentMember | 994000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 29672000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -29672000000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E02608-000MedicalProductsRetailReportableSegmentsMember | 728733000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E02608-000DispensingPharmacyReportableSegmentsMember | 47111000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 5592000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E02608-000OtherRelatedBusinessReportableSegmentMember | 3209000000 | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 784646000000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | -29672000000 | JPY |
| Net sales | Prior1InterimDuration | 754974000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E02608-000MedicalProductsRetailReportableSegmentsMember | 8005000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E02608-000DispensingPharmacyReportableSegmentsMember | -18000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 442000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E02608-000OtherRelatedBusinessReportableSegmentMember | 203000000 | JPY |
| Operating income | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 8633000000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | -1252000000 | JPY |
| Operating income | Prior1InterimDuration | 7380000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E02608-000MedicalProductsRetailReportableSegmentsMember | 714217000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E02608-000DispensingPharmacyReportableSegmentsMember | 49540000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 1298000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E02608-000OtherRelatedBusinessReportableSegmentMember | 2843000000 | JPY |
| Revenues from external customers | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 767899000000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 767899000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E02608-000MedicalProductsRetailReportableSegmentsMember | 24947000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E02608-000DispensingPharmacyReportableSegmentsMember | 2000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 4448000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E02608-000OtherRelatedBusinessReportableSegmentMember | 746000000 | JPY |
| Transactions with other segments | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 30145000000 | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | -30145000000 | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |